

---

# Table of Contents

## Section I: General Information

Chapter 1	History of EU Regulation .....	1
	<i>By Sabina Hoekstra-van den Bosch, MSc, PharmD</i>	
Chapter 2	EU Pricing and Reimbursement.....	15
	<i>Updated by Anna-Margareta Ryden, Judie Farr, and Khan Maola</i>	
Chapter 3	EU Regulatory Affairs—Health Technology Assessment .....	29
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 4	The Paediatric Regulation.....	39
	<i>Updated by Karl-Heinz Huemer, PhD, MD</i>	
Chapter 5	Advertising and Promotion .....	49
	<i>By Mag. Elisabeth Krach</i>	
Chapter 6	Enforcement and Competent Authorities.....	59
	<i>Updated by Sarah Stec, Esq, RAC</i>	
Chapter 7	Crisis Management .....	65
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 8	EU Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery.....	71
	<i>By James A. Smith, B. Naughton, A. Kramm, Graham Smith, A. Ohanjanyan, Mark De Simone, Rob Horne and David A. Brindley</i>	

## Section II: Medical Devices

Chapter 9	The New Medical Devices Regulation and In Vitro Device Regulation .....	83
	<i>By Erik Vollebregt</i>	
Chapter 10	The European Medical Devices Legal System .....	91
	<i>Updated by Gert Bos</i>	
Chapter 11	MDD and Classification of Medical Devices.....	117
	<i>Updated by Claudia Solimeo Meneghisse, PhD, RAC</i>	
Chapter 12	Active Implantable Medical Devices.....	131
	<i>Updated by Raajdeep Venkatesan, MS (MDDE, BME, EE), RAC (US, EU)</i>	
Chapter 13	In Vitro Diagnostic Medical Devices.....	135
	<i>Updated by Erik Vollebregt</i>	
Chapter 14	Essential/Technical Requirements (AIMD, MDD, IVDD) .....	145
	<i>Sharad Mi. Shukla, RAC (US, EU) and Rajaram Balasubramanian, RAC (US, EU)</i>	

Chapter 15	Clinical Evaluation.....	151
	<i>Updated by Karen Jaffe</i>	
Chapter 16	Medical Device Conformity Assessment Procedure .....	161
	<i>Updated by Ondina Iovicin-Grigorescu, RAC</i>	
Chapter 17	Medical Device Compliance: Postmarket Requirements.....	173
	<i>Updated by Melinda Harrison Smith, RAC, CBA</i>	
Chapter 18	Medical Device National Particularities.....	185
	<i>Updated by Nicole Beard, MSc, PhD</i>	

### **Section III: Medicinal Products**

Chapter 19	Overview of Authorisation Procedures for Medicinal Products.....	193
	<i>By Suzan Davis, PharmD, MBA</i>	
Chapter 20	Medicinal Product Clinical Trials .....	209
	<i>By Isabelle B. Lefebvre, MScRA, RAC (US, EU)</i>	
Chapter 21	Registration Procedures for Medicinal Products .....	233
	<i>By Hans van Bruggen, MSc</i>	
Chapter 22	Quality Systems and Inspectorate Process—Pharmaceuticals.....	253
	<i>Updated by Paula J. Shadle, PhD</i>	
Chapter 23	Generic Medicinal Products .....	261
	<i>By Reddy A. Kal, PhD, MBA, RAC (US, EU)</i>	
Chapter 24	Nonprescription Medicinal Products.....	277
	<i>By Kavitha K. Bandi, Aurelie Farfaro aand Robin Henneman</i>	
Chapter 25	Marketing Authorisations for Products Derived From Biotechnology.....	287
	<i>Updated by Devanshi Maharaja, MSc, MTech, RAC</i>	
Chapter 26	Pharmaceutical Postmarket Requirements and Compliance with the Marketing Authorisation .....	295
	<i>Updated by Kelly Miller, MSc</i>	
Chapter 27	Pharmacovigilance .....	309
	<i>Updated by John Price, MB ChB, PhD and Miranda Dollen</i>	

### **Section IV: Other Product Classifications**

Chapter 28	Products Manufactured From Human Blood or Plasma .....	323
	<i>Updated by Nicole Beard, MSc, PhD</i>	
Chapter 29	Regenerative Medicine Regulation: Cell Therapy, Gene Therapy and Tissue Engineering.....	331
	<i>By James A. Smith, Christopher A. Bravery, Georg Hollander and David A. Brindley</i>	
Chapter 30	Human Tissue Regulation.....	349
	<i>Updated by Richard van der Linden and Jeroen Pieper</i>	
Chapter 31	Vaccines .....	367
	<i>Updated by Samantha K. Zappia, MS, RAC</i>	
Chapter 32	Orphan Medicinal Products.....	379
	<i>Updated by Martine Zimmermann</i>	
Chapter 33	Combination Products.....	391
	<i>Updated by Mayank Choudhary, MS, Kathleen E. O'Sullivan MS, RAC</i>	

Chapter 34	Cosmetics Regulation in the EU .....	401
	<i>Updated by Ana Gomes</i>	
Chapter 35	The Food-Drug Borderline: A Regulatory Perspective on Food Supplements and Food for Special Medical Purposes....	409
	<i>By Manfred Ruthsatz and Patrick Coppens</i>	
Chapter 36	Veterinary Medicinal Products .....	421
	<i>Updated by Nicole Beard, MSc, PhD</i>	

## Appendices

Comparative Matrix of EU Legislation Across Product Lines .....	445
Glossary .....	479
Index .....	495

## Figures

Figure 2-1.	EU Financing and Payer Models .....	16
Figure 2-2.	Pricing and Reimbursement Principles .....	18
Figure 2-3.	Economic Evaluation Analyses .....	20
Figure 2-4.	Organisational Pricing and Reimbursement Responsibilities and Processes.....	23
Figure 2-5.	Swedish Pricing and Reimbursement Scheme.....	25
Figure 3-1.	Phased Approach to Evaluating a Health Technology .....	30
Figure 4-1.	PIP Procedure .....	44
Figure 7-1.	Crisis as a Trigger for Change .....	67
Figure 8-1.	Comparison of EU FMD and Other Countries' Falsified Medicines' Legislation .....	72
Figure 8-2.	Routes in the Medicinal Product Supply Chain by Which Falsified Active Substances may Reach Patients.....	74
Figure 8-3.	An Example of the Common Logo Online Retailers of Medicines Must Display.....	77
Figure 8-4.	Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systems .....	79
Figure 8-5.	21st Century Pharmacopeia .....	80
Figure 9-1.	Supply Chain Controls Under the MDR and IVDR .....	85
Figure 9-2.	Proposed IVD Classification Rules .....	86
Figure 10-1.	Simplified EU Legislative Process .....	93
Figure 10-2.	Flow Chart for the Conformity Assessment Procedures in Directive 93/42/EEC on Medical Devices .....	95
Figure 10-3.	Flow Chart for the Conformity Assessment Procedures in Directive 90/385/EEC on Active Implantable Medical Devices.....	96
Figure 10-4.	Flow Chart for the Conformity Assessment Procedures in Directive 98/79/EC on In Vitro Diagnostic Medical Devices.....	97
Figure 10-5.	Clinical Evaluation Cycle .....	98
Figure 11.1.	Classification Guidance Chart—Noninvasive Devices .....	120
Figure 11-2.	Classification Guidance Chart - Rule 5.....	121
Figure 11-3.	Classification Guidance Chart—Rule 6.....	122
Figure 11-4.	Classification Guidance Chart—Rule 7 .....	123
Figure 11-5.	Classification Guidance Chart—Rule 8.....	124
Figure 11-6.	Classification Guidance Chart—Active Devices .....	125
Figure 11-7.	Classification Guidance Chart—Special Rules.....	126
Figure 11-8.	IVD Classification Chart.....	127
Figure 13-1.	IVD Conformity Assessment Procedure Flowcharts .....	137
Figure 15-1.	Clinical Evaluation Flow Diagram for all Device Types .....	153
Figure 15-2.	Clinical Investigation Process Flow Diagram .....	157
Figure 16-1.	Class III Device Conformity Assessment Procedure Options.....	165
Figure 16-2.	Class IIb Conformity Assessment Procedures .....	165
Figure 16-3.	Class IIa Conformity Assessment Procedure .....	166
Figure 16-4.	Class I Device, Self-Declaration or Self-Certification.....	166
Figure 16-5.	AIMDD Conformity Assessment Procedure .....	167
Figure 16-6.	IVD Conformity Assessment Procedure .....	167
Figure 16-7.	Self-Testing IVD Conformity Assessment Procedure .....	168
Figure 16-8.	IVDD Annex II List B Conformity Assessment Procedures .....	169
Figure 16-9.	High-Risk IVD Conformity Assessment Procedure .....	169

Figure 20-1.	Iterative Improvement of Clinical Trials Legislation.....	211
Figure 20-2.	Commencement of a Clinical Trial.....	220
Figure 20-3.	Timelines and Events When Part I and Part II are Submitted Together.....	222
Figure 20-4.	Step 2A: Part I Assessment .....	223
Figure 20-5.	Step 2B: Part II Assessment by Each Member State .....	224
Figure 20-6.	Serious Adverse Event Reporting.....	226
Figure 21-1.	Initial Marketing Authorisation Application Through the Centralised Procedure .....	244
Figure 21-2.	Initial Marketing Authorisation Application Through the Decentralised Procedure.....	246
Figure 21-3.	Initial Marketing Authorisation Application through National Procedure and Mutual Recognition Procedure.....	249
Figure 27-1.	Pharmacovigilance System Master File .....	312
Figure 27-2.	ICSR expedited submissions requirements .....	316
Figure 27-3.	Signal Management Lifecycle .....	318
Figure 29-1.	Decision Tree for Classification of TEPs and CTMPs.....	337
Figure 29-2.	Decision Tree for GTMP Classification .....	339
Figure 30-1.	355	
Figure 31-1.	General Principles of VAMF.....	372
Figure 31-2.	Diagram of the Process for Production and Licensing of Influenza Vaccines in the European Union (EU) (re-created from Minor 2010) .....	376
Figure 31-3.	Pandemic Influenza Vaccine Manufacturing Process and Timeline .....	377
Figure 32-1.	Simplified View of the Designation Criteria .....	383
Figure 32-2.	Simplified View of the Orphan Drug Designation Process .....	386
Figure 33-1.	Consultation Procedure and Timeline .....	395

## Tables

Table 2-1.	Transparency Directive Implementation Case Studies.....	17
Table 2-2.	EU Member State Pricing Schemes .....	26
Table 3-1.	REA Checklist.....	34
Table 8-1.	Definitions of Key Terms in This Chapter .....	73
Table 8-2.	Worldwide Examples of SFFC Medicines From 2008 to Present <sup>1,2</sup> .....	75
Table 8-3.	Different Medicinal Product Supply Chain Stakeholder Requirements Under the <i>FMD</i> .....	76
Table 8-4.	<i>FMD</i> Definitions of Active Substances and Excipients.....	77
Table 8-5.	EU Initiatives Relevant to the <i>FMD</i> .....	78
Table 8-6.	List and Status of Third Countries Requested to be Listed .....	80
Table 8-7.	Examples of Stratified Medicines and Companion Diagnostics.....	81
Table 10-1.	New Approach Areas .....	94
Table 10-2.	EU Member States and Affiliated Countries Competent Authorities .....	100
Table 10-3.	European Commission Working Groups and Their Activities.....	102
Table 10-4.	European Industrial Trade Associations .....	104
Table 10-5.	MEDDEV Guidance Documents .....	108
Table 10-6.	European Commission Consensus Statements.....	110
Table 10-7.	Informative Documents Issued by the European Commission.....	111
Table 10-8.	NBOG Documents (NBOG Best Practice Guides).....	112
Table 12-1.	Comparison of <i>AIMDD</i> and <i>MDD</i> Annexes .....	133
Table 13-1.	Examples of General Laboratory Use Products and IVD Medical Devices .....	138
Table 14-1.	Essential Requirements – Annex I, 93/42/EEC as amended by Directive 2007/47/EC (Example).....	146
Table 15-1.	Abbreviations and Terms Used in This Chapter .....	154
Table 15-2.	Examples of Multiple Approvals and Timelines in Some EU Member States .....	158
Table 16-1.	Conformity Assessment Procedures .....	162
Table 16-2.	<i>AIMDD</i> Conformity Assessment Documentation .....	163
Table 16-3.	<i>MDD</i> Conformity Assessment Documentation .....	164
Table 16-4.	<i>IVDD</i> Conformity Assessment Documentation .....	164
Table 16-5.	Internal Production Control.....	170
Table 16-6.	EC Type-Examination .....	170
Table 16-7.	Production Quality Assurance .....	170
Table 16-8.	Product Quality Assurance .....	170
Table 16-9.	Product Verification.....	170
Table 16-10.	Full Quality Assurance System .....	170
Table 16-11.	Authorised Representatives.....	170

Table 17-1.	Provisions for Providing Feedback about Medical Devices .....	175
Table 17-2.	EUDAMED Data Repository .....	176
Table 17-3.	Comparison of Safeguard Clause and Health Monitoring Measures .....	181
Table 18-1.	Relevant Authorities in Germany .....	191
Table 19-1.	Standard Timetable for Evaluation of a Centralised Application .....	199
Table 19-2.	Mutual Recognition Procedure Flowchart .....	201
Table 19-3.	Decentralised Procedure Flowchart.....	205
Table 20-1.	Summary of Selected Significant Changes Under Regulation (EU) No 536/2014 ECTR .....	212
Table 20-2.	Definitions of Selected <i>Clinical Trials Directive</i> and <i>ECTR</i> Terms .....	215
Table 20-3.	General Contents of Applications to Ethics Committees and National Competent Authorities .....	218
Table 20-4.	Contents of Clinical Trial Application Dossier per the <i>ECTR</i> .....	225
Table 20-5.	Contents of DSUR.....	228
Table 21-1.	EU Module 1 Contents.....	241
Table 21-2.	EU eCTD Envelope Information .....	242
Table 24-1.	Some Common Health Conditions Treated Using Nonprescription Medication .....	278
Table 24-2.	Comparison of EU MAA Procedure Advantages and Risks for Nonprescription Medicines.....	279
Table 27-1.	Overview of Good Pharmacovigilance Practices .....	311
Table 27-2.	Periodic Benefit Risk Evaluation Report (PBRER), Development Safety Update Report (DSUR) and Risk Management Plan (RMP) Interchangeable Modules .....	315
Table 28-1.	Medicinal Products Derived From Human Plasma and Their Indications.....	325
Table 29-1.	ATMPs and Their Status in the EU, INN (International Nonproprietary Name) .....	333
Table 29-2.	Substantial and Not Substantial Manipulations .....	334
Table 29-3.	ATMP Classification Definitions: GTMPs CTMPs, TEPs and Combined ATMPs .....	335
Table 29-4.	Recent Examples ATMP Classification Outcomes by the CAT.....	336
Table 29-5.	Guidance Documents Available for Cell Therapy Medicinal Products and Tissue-Engineered Products.....	338
Table 29-6.	Guidance Documents Available for Gene Therapy Medicinal Products .....	340
Table 29-7.	Definition of Starting Materials, Drug Substance and Drug Product .....	344
Table 30-1.	Serological Donor Testing Requirements .....	352
Table 30-2.	Structure of the Single European Code.....	356
Table 30-3.	General Applicable Regulatory Framework for Medical Products Containing Human Tissue Intended for Human Clinical Use and its Interconnection With the Tissues and Cells Directive 2004/23/EC.....	358
Table 30-4.	General and Specific Market Access Requirements for Tissue- and Cell-Based Products, Excluding ATMPs.....	360
Table 30-5.	Qualifications and Responsibilities of the Responsible Person Under the <i>EUTCD</i> versus the Qualified Person for Human Medicinal Products .....	362
Table 31-1.	General Vaccine Guidelines.....	370
Table 31-2.	Influenza Guidelines.....	374
Table 32-1.	Comparison of the EU, US and Japanese Orphan Programmes <sup>a,b,c</sup> .....	382
Table 33-1.	Comparison of Key Combination Product References in Council Directive 93/42/EEC and the Proposed Regulation .....	396
Table 34-1.	Main Legislation and Authorities Regulating Cosmetic Products Around the Globe*.....	407
Table 36-1.	Legislative Framework for Registration of Veterinary Medicinal Products Within the EEA.....	426
Table 36-2.	Competent Authorities for the Regulation of Veterinary Medicines in the EEA.....	431
Table 36-3.	Food-producing Species .....	435
Table 36-4.	MUMS Guidelines.....	438